NCT04906304View on ClinicalTrials.gov

Comparison of Safety and Efficacy of de Novo Everolimus

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

July 1, 2020

Study Completion Date

August 1, 2020

Conditions
Cytomegalovirus Infections
Interventions
DRUG

Everolimus Pill

standard dose versus low dose Sandimun

DRUG

Sandimmun (Neoral) dose plus cellcept

Sandimmun (Neoral) dose plus cellcept

Trial Locations (1)

Unknown

Nooshin Dalili, Tehran

All Listed Sponsors
lead

Shahid Beheshti University of Medical Sciences

OTHER

NCT04906304 - Comparison of Safety and Efficacy of de Novo Everolimus | Biotech Hunter | Biotech Hunter